Tumor Necrosis Factor Receptor Superfamily, Member 9
"Tumor Necrosis Factor Receptor Superfamily, Member 9" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A member of the tumor necrosis factor receptor superfamily that is specific for 4-1BB LIGAND. It is found in a variety of immune cell types including activated T-LYMPHOCYTES; NATURAL KILLER CELLS; and DENDRITIC CELLS. Activation of the receptor on T-LYMPHOCYTES plays a role in their expansion, production of cytokines and survival. Signaling by the activated receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.
| Descriptor ID |
D053261
|
| MeSH Number(s) |
D12.776.543.750.705.852.760.220
|
| Concept/Terms |
Tumor Necrosis Factor Receptor Superfamily, Member 9- Tumor Necrosis Factor Receptor Superfamily, Member 9
- 4-1BB Receptor
- 4 1BB Receptor
- Receptor, 4-1BB
- CD137 Antigen
- Antigen, CD137
- CD137 Antigens
- Antigens, CD137
- TNFRSF9 Receptor
- Receptor, TNFRSF9
- 4-1BB Receptors
- 4 1BB Receptors
- Receptors, 4-1BB
|
Below are MeSH descriptors whose meaning is more general than "Tumor Necrosis Factor Receptor Superfamily, Member 9".
Below are MeSH descriptors whose meaning is more specific than "Tumor Necrosis Factor Receptor Superfamily, Member 9".
This graph shows the total number of publications written about "Tumor Necrosis Factor Receptor Superfamily, Member 9" by people in this website by year, and whether "Tumor Necrosis Factor Receptor Superfamily, Member 9" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 1 | 0 | 1 |
| 2018 | 2 | 0 | 2 |
| 2019 | 2 | 0 | 2 |
| 2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Tumor Necrosis Factor Receptor Superfamily, Member 9" by people in Profiles.
-
Successful treatment of COVID-19 infection with convalescent plasma in B-cell-depleted patients may promote cellular immunity. Eur J Immunol. 2021 10; 51(10):2478-2484.
-
Storm of soluble immune checkpoints associated with disease severity of COVID-19. Signal Transduct Target Ther. 2020 09 07; 5(1):192.
-
Clearance of Chikungunya Virus Infection in Lymphoid Tissues Is Promoted by Treatment with an Agonistic Anti-CD137 Antibody. J Virol. 2019 12 15; 93(24).
-
Chronic retroviral infection of mice promotes tumor development, but CD137 agonist therapy restores effective tumor immune surveillance. Cancer Immunol Immunother. 2019 Mar; 68(3):479-488.
-
Limited Cross-Linking of 4-1BB by 4-1BB Ligand and the Agonist Monoclonal Antibody Utomilumab. Cell Rep. 2018 10 23; 25(4):909-920.e4.
-
Immune active cells with 4-1BB signal enhancement inhibit hepatitis B virus replication in noncytolytic manner. Cell Immunol. 2018 06; 328:79-85.
-
CD137 is expressed in human atherosclerosis and promotes development of plaque inflammation in hypercholesterolemic mice. Circulation. 2008 Mar 11; 117(10):1292-301.